VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in Ginkgo Bioworks Holdings, Inc. $DNA

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 13,200 shares of the company’s stock, valued at approximately $148,000.

Several other large investors have also recently modified their holdings of the business. Goldman Sachs Group Inc. raised its stake in shares of Ginkgo Bioworks by 25.4% during the first quarter. Goldman Sachs Group Inc. now owns 686,767 shares of the company’s stock valued at $3,915,000 after acquiring an additional 139,126 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Ginkgo Bioworks during the first quarter valued at $120,000. Millennium Management LLC raised its stake in shares of Ginkgo Bioworks by 113.1% during the first quarter. Millennium Management LLC now owns 1,427,600 shares of the company’s stock valued at $8,137,000 after acquiring an additional 757,535 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Ginkgo Bioworks by 322.6% during the first quarter. AQR Capital Management LLC now owns 158,939 shares of the company’s stock valued at $906,000 after acquiring an additional 121,326 shares during the last quarter. Finally, PDT Partners LLC raised its stake in shares of Ginkgo Bioworks by 104.0% during the first quarter. PDT Partners LLC now owns 385,153 shares of the company’s stock valued at $2,195,000 after acquiring an additional 196,350 shares during the last quarter. Institutional investors own 78.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ginkgo Bioworks in a research note on Friday. Cowen reissued a “buy” rating on shares of Ginkgo Bioworks in a research note on Friday, August 8th. BTIG Research lifted their target price on shares of Ginkgo Bioworks from $6.00 to $9.00 and gave the stock a “sell” rating in a research note on Monday, August 25th. Finally, Wall Street Zen raised shares of Ginkgo Bioworks from a “sell” rating to a “hold” rating in a research note on Saturday, August 30th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Ginkgo Bioworks presently has a consensus rating of “Reduce” and a consensus price target of $9.00.

Ginkgo Bioworks Price Performance

NYSE DNA opened at $13.61 on Monday. The business has a 50 day simple moving average of $12.69 and a 200 day simple moving average of $10.62. Ginkgo Bioworks Holdings, Inc. has a one year low of $5.00 and a one year high of $17.58. The stock has a market capitalization of $805.89 million, a P/E ratio of -2.32 and a beta of 1.54.

Ginkgo Bioworks (NYSE:DNA) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.44) by $0.34. The firm had revenue of $49.60 million during the quarter, compared to the consensus estimate of $41.60 million. Ginkgo Bioworks had a negative net margin of 136.56% and a negative return on equity of 43.25%. Ginkgo Bioworks has set its FY 2025 guidance at EPS. Equities analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Steven P. Coen sold 5,609 shares of the business’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $15.00, for a total transaction of $84,135.00. Following the transaction, the insider directly owned 5,503 shares in the company, valued at approximately $82,545. The trade was a 50.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 9.72% of the company’s stock.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.